Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#26 / 26 Total
XRTX - XORTX Therapeutics Inc - Stock Price Chart
TickerXRTX [NASD]
CompanyXORTX Therapeutics Inc
CountryCanada
IndustryBiotechnology
Market Cap4.93MEPS (ttm)-1.41
P/E-EPS this Y-63.97%
Forward P/E-EPS next Y46.29%
PEG-EPS past 5Y26.21%
P/S-EPS next 5Y-
P/B2.87EPS Q/Q-30.88%
Dividend-Sales Q/Q-
Insider Own10.30%Inst Own9.33%
Insider Trans0.00%Inst Trans-
Short Float0.49%EarningsMay 20/b
Analyst Recom1.00Target Price12.15
Avg Volume50.13K52W Range1.98 - 7.52
May-20-24 11:53AM XRTX Stock Earnings: XORTX Therapeutics Reported Results for Q1 2024 (InvestorPlace)
May-17-24 07:00AM XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO (GlobeNewswire) +6.38%
Apr-30-24 01:54PM XORTX Reprices Warrants Issued in Connection with Previous Private Placements (GlobeNewswire)
Apr-22-24 07:00AM XORTX Announces Publication of Key Research in ADPKD (GlobeNewswire)
Apr-08-24 07:30AM XORTX Welcomes New Member to the Board of Directors (GlobeNewswire) +5.53%
07:00AM XORTX Announces Participation in Spring 2024 Investor Conferences (GlobeNewswire)
Mar-27-24 05:00AM XORTX Announces New Clinical Advisory Board Member (GlobeNewswire) -5.26%
Mar-19-24 09:30AM XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial (News Direct)
05:00AM XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial (GlobeNewswire)
Mar-11-24 07:00AM XORTX Reprices Warrants Issued in Connection with Previous Private Placements (GlobeNewswire) -6.71%
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
123
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.